As of 2026-02-17, the EV/EBITDA ratio of Intellia Therapeutics Inc (NTLA) is -2.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NTLA's latest enterprise value is 1,181.51 mil USD. NTLA's TTM EBITDA according to its financial statements is -468.77 mil USD. Dividing these 2 quantities gives us the above NTLA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.6x | 15.4x |
| Forward P/E multiples | 14.0x - 38.4x | 24.5x |
| Fair Price | (54.83) - (61.63) | (79.07) |
| Upside | -561.9% - -619.2% | -766.1% |
| Date | EV/EBITDA |
| 2026-02-17 | -2.50 |
| 2026-02-13 | -2.52 |
| 2026-02-12 | -2.46 |
| 2026-02-11 | -2.55 |
| 2026-02-10 | -2.53 |
| 2026-02-09 | -2.67 |
| 2026-02-06 | -2.62 |
| 2026-02-05 | -2.33 |
| 2026-02-04 | -2.64 |
| 2026-02-03 | -2.81 |
| 2026-02-02 | -2.81 |
| 2026-01-30 | -2.84 |
| 2026-01-29 | -3.02 |
| 2026-01-28 | -3.00 |
| 2026-01-27 | -3.25 |
| 2026-01-26 | -3.03 |
| 2026-01-23 | -3.20 |
| 2026-01-22 | -3.52 |
| 2026-01-21 | -3.05 |
| 2026-01-20 | -2.76 |
| 2026-01-16 | -2.68 |
| 2026-01-15 | -2.52 |
| 2026-01-14 | -2.56 |
| 2026-01-13 | -2.49 |
| 2026-01-12 | -2.41 |
| 2026-01-09 | -2.15 |
| 2026-01-08 | -2.19 |
| 2026-01-07 | -2.09 |
| 2026-01-06 | -1.99 |
| 2026-01-05 | -1.90 |
| 2026-01-02 | -1.86 |
| 2025-12-31 | -1.81 |
| 2025-12-30 | -1.83 |
| 2025-12-29 | -1.85 |
| 2025-12-26 | -1.92 |
| 2025-12-24 | -1.96 |
| 2025-12-23 | -1.92 |
| 2025-12-22 | -1.98 |
| 2025-12-19 | -1.87 |
| 2025-12-18 | -1.78 |
| 2025-12-17 | -1.76 |
| 2025-12-16 | -1.84 |
| 2025-12-15 | -1.85 |
| 2025-12-12 | -1.82 |
| 2025-12-11 | -1.95 |
| 2025-12-10 | -1.90 |
| 2025-12-09 | -1.89 |
| 2025-12-08 | -1.92 |
| 2025-12-05 | -1.96 |
| 2025-12-04 | -1.99 |